Peter BÜHLER

About Peter BÜHLER

Peter Bühler is an internationally experienced finance executive known for his track record in the life sciences and technology sectors. He currently serves as Chief Financial Officer of Valneva SE, a specialty vaccine company, having joined the group in January 2022. Following Valneva’s governance transition in late 2023, he is also referenced among the company’s executive leaders as an Associate Managing Officer. Before joining Valneva, Peter Bühler held senior finance leadership roles at Quotient, Zaluvida AG, and Stallergenes Greer Plc, where he led a major French-U.S. merger. That transaction is a notable part of his background, reflecting experience in cross-border integration, governance, and value creation in complex international environments. Earlier in his career, he also held senior positions at Eli Lilly, Merck Serono, and Logitech, building a broad base of expertise across highly regulated, innovation-driven businesses. A Swiss national, he is a Swiss Certified Accountant and holds an MBA. His profile combines strong financial discipline, operational judgment, and deep familiarity with international corporate structures. At Valneva, those capabilities are particularly important because the company operates in a capital-intensive biotech setting that requires careful treasury management, disciplined investment prioritization, and effective capital markets communication. Bühler has played a visible role in Valneva’s financing strategy, including the expansion of the company’s debt facility with Deerfield and OrbiMed in 2022 and 2023, as well as the private placement completed in 2024. These transactions supported R&D spending, launch readiness, and liquidity needs as Valneva advanced its vaccine portfolio. His mandate highlights practical expertise in corporate finance, non-dilutive and equity financing, and capital allocation in a specialized vaccine business.